Grail's Galleri Test Fails Later-Stage Cancer Detection in Major Study

MarketWatch reported that a recent study found Grail’s Galleri test could not demonstrate effectiveness in detecting later-stage cancers. The test uses a simple blood draw to screen for 50 different types of cancer. However, the study results revealed a specific limitation: the inability to prove detection rates for cancers that have progressed beyond early stages.

Detecting later-stage tumors is a mandatory requirement for the U.S. Food and Drug Administration to approve a cancer screening product. Without this validation, Grail cannot secure the regulatory clearance needed to make the test available through major health insurance programs, including Medicare. Insurance providers typically require FDA approval before adding a new diagnostic tool to their covered benefits. Currently, the test remains limited to out-of-pocket use or specific clinical settings.